Document is current
Any future updates will be listed below
-
Authors
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Talpaz, Moshe https://orcid.org/0000-0003-3361-3981
Saglio, Giuseppe https://orcid.org/0000-0002-1046-3514
Cortes, Jorge E. https://orcid.org/0000-0002-8636-1071
Hughes, Timothy https://orcid.org/0000-0002-0910-3730
Apperley, Jane https://orcid.org/0000-0002-1710-1794
Hantschel, Oliver https://orcid.org/0000-0001-8569-8169
Rea, Delphine
Schuld, Peter
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
-
Funding
Funding for this research was provided by:
Novartis (Not applicable)
- License Information
-
More Information
Article History
Received: 1 May 2026
Revised: 6 May 2026
Accepted: 7 May 2026
First Online: 22 May 2026
Competing interests
: AH has received honoraria from Novartis (institutional), Incyte (institutional); has a consulting or advisory role for Novartis, Incyte; has received research funding from Bristol Myers Squibb (institutional), Enliven Therapeutics (institutional), Incyte (institutional), Novartis (institutional), Pfizer (institutional), Terns Pharmaceuticals (institutional); has received travel, accommodations and expenses from Johnson & Johnson, Novartis. MT has an unpaid leadership role in the Society of Hematology Oncology (SOHO); has participated in advisory board meetings for Sumitomo; has received research funding from BMS. GS has received fees for consultancy and speaker’s bureau from Ascentage Pharma, Hikma, Novartis. JEC has served as a consultant or in an advisory role for Lilly, Novartis, Terns Pharma, Astellas, Crossbow, Ascentage, Rigel, Sun Pharma, Syndax, Xspray; has received payment for lectures from Novartis, Pfizer, Takeda; has received research funding from AbbVie, Ascentage, Novartis, Sun Pharma, Terns Pharma, CytoAgents; has received stock options from Bio-Path Holdings. TH has received honoraria for advisory boards and symposia from Novartis, Takeda, Terns; has received research funding from Novartis. JA has received honoraria for advisory boards/consultancies/speaker’s bureau from Ascentage, Incyte, Novartis, Paladin, Terns; has received institutional research support from Incyte, Pfizer; has received honoraria from Incyte, Novartis has participated in speaker’s bureau for Bristol Myers Squibb, Incyte, Novartis, Pfizer. OH has received funding from Novartis through the European Treatment and Outcome Study for CML (EUTOS); has received speakers’ honoraria from Novartis. DR has participated in advisory board meetings for Ascentage Pharma, Enliven, Novartis, TERNS; has acted as consultant for Novartis, TERNS; has received honoraria from Ascentage Pharma, Enliven, Incyte, Novartis, and TERNS. PS is an employee of Novartis. HK has received honoraria from AbbVie, Amgen, Pfizer, Ascentage Pharma Group, Ipsen, KAHR Medical, Novartis, Shenzhen Target Rx, Daiichih-Sankyo (institutional), Immunogen (institutional); has a consulting or advisory Role for AbbVie; has received institutional research funding from AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi Sankyo/Lilly, Immunogen, Jazz Pharmaceuticals, Novartis.
